Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patients.

Nicholas J, Ko JJ, Park Y, Navaratnam P, Friedman HS, Ernst FR, Herrera V.

Mult Scler J Exp Transl Clin. 2017 Mar 17;3(1):2055217317696114. doi: 10.1177/2055217317696114. eCollection 2017 Jan-Mar.

2.

Optic neuritis as an early sign of multiple sclerosis.

Kale N.

Eye Brain. 2016 Oct 26;8:195-202. doi: 10.2147/EB.S54131. eCollection 2016. Review.

3.

New developments in the treatment of optic neuritis.

Jenkins TM, Toosy AT.

Eye Brain. 2010 Jun 17;2:83-94. eCollection 2010.

4.

Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE.

Benešová Y, Tvaroh A.

Ther Adv Neurol Disord. 2017 Jan;10(1):18-32. doi: 10.1177/1756285616671882. Epub 2016 Oct 21.

5.

Clinically Isolated Syndromes: Clinical Characteristics, Differential Diagnosis, and Management.

Efendi H.

Noro Psikiyatr Ars. 2015 Dec;52(Suppl 1):S1-S11. doi: 10.5152/npa.2015.12608. Epub 2015 Dec 1. Review.

6.

Narrowband UVB Phototherapy for Clinically Isolated Syndrome: A Trial to Deliver the Benefits of Vitamin D and Other UVB-Induced Molecules.

Hart PH, Lucas RM, Booth DR, Carroll WM, Nolan D, Cole JM, Jones AP, Kermode AG.

Front Immunol. 2017 Jan 24;8:3. doi: 10.3389/fimmu.2017.00003. eCollection 2017.

7.

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.

Uher T, Fellows K, Horakova D, Zivadinov R, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Bergsland N, Weinstock-Guttman B, Havrdova E, Ramanathan M.

J Lipid Res. 2017 Feb;58(2):403-411. doi: 10.1194/jlr.M072751. Epub 2016 Dec 6.

PMID:
27923871
8.

Multiple functions of USP18.

Honke N, Shaabani N, Zhang DE, Hardt C, Lang KS.

Cell Death Dis. 2016 Nov 3;7(11):e2444. doi: 10.1038/cddis.2016.326. Review.

9.

The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.

Dupuy SL, Khalid F, Healy BC, Bakshi S, Neema M, Tauhid S, Bakshi R.

BMC Med Imaging. 2016 Oct 5;16(1):56.

10.

Interferons as Therapy for Viral and Neoplastic Diseases: From Panacea to Pariah to Paragon.

Friedman RM, Contente S.

Pharmaceuticals (Basel). 2009 Dec 15;2(3):206-216. Review.

11.

Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome.

Jernas Ł, Wencel J, Wiak A, Bieniek M, Bartosik-Psujek H.

PLoS One. 2016 Oct 3;11(10):e0157950. doi: 10.1371/journal.pone.0157950. eCollection 2016.

12.

McDonald Criteria 2010 and 2005 Compared: Persistence of High Oligoclonal Band Prevalence Despite Almost Doubled Diagnostic Sensitivity.

Schwenkenbecher P, Sarikidi A, Wurster U, Bronzlik P, Sühs KW, Raab P, Stangel M, Pul R, Skripuletz T.

Int J Mol Sci. 2016 Sep 21;17(9). pii: E1592.

13.

Results of sustained long-term use of interferon beta-1a in a community-based cohort of patients with relapsing multiple sclerosis.

Cohan S, Chen C, Baraban E, Stuchiner T, Grote L, Rodriguez M.

J Drug Assess. 2015 Feb 7;4(1):1-6. doi: 10.3109/21556660.2015.1010650. eCollection 2015.

14.

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.

15.

Update on immunopathogenesis and immunotherapy in multiple sclerosis.

Selter RC, Hemmer B.

Immunotargets Ther. 2013 Apr 25;2:21-30. doi: 10.2147/ITT.S31813. eCollection 2013. Review.

16.

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.

Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Marantz JL.

Neurol Ther. 2016 Jun;5(1):45-57. doi: 10.1007/s40120-016-0042-8. Epub 2016 Mar 1.

17.

Optimizing treatment success in multiple sclerosis.

Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S.

J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24. Review.

18.

Placebo-controlled study in neuromyelitis optica-Ethical and design considerations.

Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E.

Mult Scler. 2016 Jun;22(7):862-72. doi: 10.1177/1352458515620934. Epub 2015 Dec 14.

19.

Disease-modifying treatments for multiple sclerosis - a review of approved medications.

Torkildsen Ø, Myhr KM, Bø L.

Eur J Neurol. 2016 Jan;23 Suppl 1:18-27. doi: 10.1111/ene.12883. Review.

20.

The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis.

Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I, Papathanasopoulos P, Dardiotis E, Kilidireas C, Voumvourakis K; HELANI (Hellenic Academy of Neuroimmunology).

Ther Adv Neurol Disord. 2015 Sep;8(5):193-202. doi: 10.1177/1756285615600381.

Supplemental Content

Support Center